Recursion Pharmaceuticals

Update in progress

RXRX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Recursion Pharmaceuticals, Inc. is a clinical-stage biotech that accelerates drug discovery by integrating biology, chemistry, automation, data science, and engineering in the U.S. and U.K. Programs: REC-4881 (Phase 1b/2 for familial adenomatous polyposis), REC-617 (Phase 1/2 solid tumors), REC-1245 (Phase 1/2 biomarker-enriched tumors and lymphoma), REC-3565 (Phase 1/2 B-cell malignancies), and REC-4539 (LSD1 inhibitor for solid tumors and hematology). Preclinical: REC-7735, REC-102. Collaborations: Roche/Genentech, Sanofi, Bayer, Tempus, Takeda. Based in Salt Lake City, founded 2013.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.07; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive